All In Biotech

NDA 019194 · Bausch

Syprine

Trientine Hydrochloride · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 3, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Nov 8, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

5 Phase 3, 1 recruiting

FAERS reports

184

106 serious, 18 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2020.

INDICATIONS AND USAGE Syprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. Syprine should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, Syprine is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, Syprine was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Syprine is not indicated for treatment of biliary cirrhosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 8, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • SYPRINE · TRIENTINE HYDROCHLORIDE 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Trientine" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dose omission19
  • therapy interrupted17
  • product storage error13
  • drug ineffective11
  • insurance issue11
  • treatment noncompliance11
  • condition aggravated10
  • nausea10
  • enteritis9
  • hepato-lenticular degeneration9
  • no adverse event9
  • death8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20066
20072
20101
20111
20121
20144
20153
201614
201741
201820
201912
202017
202120
20224
20238
202410
20259
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Syprine (Trientine HCl)

2024 spending

$1.4M

Beneficiaries

n/a

61 claims

Per beneficiary

n/a

$198.83 per unit

View as table
YearSpending
2020$2,666,049
2021$766,879
2022$617,408
2023$702,348
2024$1,437,525

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.